Leo Pharma A/S is again raising its bet on the promise of biologics to address important skin diseases, dealing in Morphosys AG and its Ylanthia antibody platform for a multi-target deal. The collaboration could yield multiple new dermatology therapies and milestone payments for Morphosys of up to €111.5 million (US$123.9 million) per program.